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ABSTRACT
Introduction: The guidelines recommend a
beta-blocker or calcium channel blocker as the
first-line medication for angina, supplemented
by other agents for additional symptoms. One
such agent is trimetazidine (TMZ), which has
been shown to reduce the frequency of anginal
episodes and improve exercise performance
without affecting haemodynamic parameters.
However, extensive real-world evidence for its
efficacy in combination with first-line therapies
has been lacking.
Methods: The aim of this large-scale, Russian,
multicentre, 6-month, open-label, prospective
observational study was to assess the effect of
adding TMZ modified release 35 mg bid to
background antianginal therapy in the real--
world clinical setting.
Results: The study included 896 patients: 54%
women, aged 29–90 years (42.6% [65 years),
63% with class II angina, and receiving
beta-blockers alone or in combination (93%).
Add-on TMZ reduced angina frequency and
short-acting nitrate use within 2 weeks (both
p\0.0001) regardless of background therapy
and maintained this effect over 6 months. It
increased the proportion of patients with class I
angina sixfold while decreasing that of class 3
angina almost fourfold. It also improved walk-
ing distance and well-being at 6 months (both
p\0.0001). Treatment was well tolerated.
Conclusion: Add-on TMZ is a safe and rapidly
effective treatment for reducing angina attacks
and nitrate use in the real-world clinical setting.
It also increases exercise capacity and well-be-
ing. These effects are observed within 2 weeks
and persist for at least 6 months.
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INTRODUCTION
Angina is the cardinal symptom of coronary
artery disease (CAD), the associated disability,
morbidity and mortality of which [1, 2] signifi-
cantly impair quality of life [3–5]. Patients with
stable angina have high rates of chest pain
requiring hospitalisation and resource utilisa-
tion [6, 7]. Any increased incidence of angina is
associated with higher hospitalisation rates.
Angina is also associated with an increased risk
of major adverse cardiovascular event (MACE)
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outcomes (cardiovascular mortality, hospitali-
sation for myocardial infarction, heart failure or
stroke) [8].
Drugs are the mainstay treatment, playing a
fundamental role in preventing risk, relieving
pain, reducing attack frequency and improving
quality of life. Evidence-based management is
crucial [9] and supports the option of mul-
ti-drug therapy [10]: in the prospective Euro
Heart Survey most patients (59%) received two
or more antianginal drugs [11]. The evidence
also shows that improved therapeutic strategies
are needed. One reason is that as CAD patients
increase in age and number, so angina preva-
lence increases with age [12]. Another reason is
that even strategies based on current optimal,
multiple, evidence-based medical therapy with
or without revascularisation may fail to reduce
MACE outcomes or eliminate angina: up to 40%
of patients in the COURAGE trial experienced
recurrent angina despite the different strategies
applied [4].
Current guidelines state ‘‘Optimal medical
treatment indicates at least one drug for angina/
ischaemia relief plus drugs for event preven-
tion’’ and recommend beta-blocker monother-
apy or beta-blocker and dihydropyridine
calcium channel blocker combination therapy
as the first-line medication for reducing angina/
ischaemia severity; various other agents may be
considered for improving additional symptoms
[10].
Trimetazidine (TMZ) is cytoprotective during
ischaemia and thus indicated in the long-term
treatment of stable angina. Its effects comple-
ment those of haemodynamically active agents.
It reduces the frequency of anginal episodes and
improves exercise performance without affect-
ing haemodynamic parameters [13, 14]. Car-
dioprotection [15–18] has been demonstrated in
both animal models [19, 20] and patients,
whether with CAD [14, 21–24] or heart failure
[25–28]. TMZ acts by optimising ATP produc-
tion directly at the cardiac cell level and
opposing ischaemic change [16].
The different mechanisms of action of
anti-ischaemic drugs permit personalised treat-
ments tailored to comorbidity and cardiac
function [9]. Certain drug combinations may
thus prove additive or even synergistic.
CHOICE-2 was designed to assess the impact
over 6 months of adding TMZ modified release
(MR) 35 mg bid to background antianginal
therapy in the real-world clinical setting.
METHODS
CHOICE-2 was a 6-month non-interventional,
multicentre, open-label, prospective observa-
tional study conducted in Russia from Septem-
ber 2014 to September 2015 in a real-world
clinical setting. Diagnosis, treatment and mon-
itoring were exclusively physician-led, deter-
mined by the indications and contraindications
of the medicinal products at the disposal of the
general practitioner or cardiologist concerned.
From inclusion onwards, physicians were free to
modify treatment in the light of their own
expertise and established clinical practice.
Inclusion was decided solely by physicians
according to the medical merit and necessity of
treatment with TMZ 35 mg bid.
The inclusion criteria were men and women
[18 years of age providing their informed con-
sent, with a C3-month history of stable angina
documented by ECG-confirmed myocardial
ischaemia and/or prior myocardial infarction,
revascularisation or [50% coronary stenosis,
and treated for CAD in the past month.
Non-inclusion criteria were: Canadian Cardio-
vascular Society (CCS) class 4 stable angina;
hospitalisation in the past 3 months for acute
coronary syndrome (infarction or unstable ang-
ina); uncontrolled hypertension (systolic
[180 mmHg or diastolic [100 mmHg) despite
ongoing antihypertensive treatment; New York
Heart Association (NYHA) class III or IV heart
failure; pregnancy or breast feeding; CAD sur-
gery scheduled in the next 6 months; severe
hepatic or renal failure, or other severe chronic
disease requiring continuous treatment; known
poor treatment compliance; intolerance or
contraindications to TMZ.
The protocol stipulated five visits: inclusion,
week 2 (W2) and months 2, 4 and 6 (M2, M4,
M6). At inclusion, eligible patients were
informed about the study and TMZ and asked to
provide their written consent. Case report forms
(CRFs) were completed with the following data:
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general and cardiovascular history, cardiovas-
cular risk factors, concomitant diseases, con-
comitant medication, heart rate, blood pressure,
number of anginal attacks in the preceding
week and short-acting nitrate consumption.
Patients were assigned a CCS [29] and NYHA
[30] class, exercise tolerance was measured by
the walking distance eliciting angina, and
well-being on a visual analog scale (VAS) graded
0–100 (maximal well-being). Investigators
maintained the CRFs throughout treatment.
Compliance with Ethics Guidelines
All procedures complied with the ethical stan-
dards of the responsible committee on human
experimentation (institutional and national),
the Helsinki Declaration of 1964, as revised in
2013, and the European Independent Ethics
Committee. The CHOICE-2 protocol was
approved by the Inter-University Ethics Com-
mittee (protocol no. 09-14 dd. 23/10/2014;
Moscow), and informed consent to inclusion in
the study was obtained from all patients.
Statistical Analysis
Descriptive statistics were used for data analysis:
mean, standard deviation (SD), range and
median for normally distributed continuous
variables and mean, SD, range, median and first
and third quartiles for non-normally distributed
continuous variables.
For qualitative and quantitative variables
having few possible values, we calculated the
absolute and relative incidences of each pos-
sible value. We compared quantitative vari-
ables before and after treatment within the
same population or group using Student’s
t test for normally distributed paired samples
and Wilcoxon’s test for non-normally dis-
tributed variables. To compare two study
groups we used Student’s t test for indepen-
dent samples in case of normally distributed
quantitative variables and the Mann-Whitney
test for non-normally distributed quantitative
variables; we used the v2 test for qualitative
parameters. All tests were two-sided with a
significance level of 0.05.
RESULTS
Population
896 patients with stable angina were enrolled by
185 doctors from 46 regions of the Russian
Federation; 35.5% were visiting the study
physician for the first time, 59.5% were already
the physician’s patients, and approximately 4%
did not answer. Demographic and baseline
clinical characteristics (Table 1) showed a
majority of women (54%) and an age range
from 29 to 90 years, with a high proportion of
elderly (42.6%[65 years). Most had hyperten-
sion; 70.1% had never smoked; 14% were for-
mer smokers. Only 16.3% had a normal body
mass index; 44% were obese. CAD interven-
tions, reported in 17.4%, comprised percuta-
neous coronary intervention (7.1%), coronary
artery bypass grafting (5.0%) and unspecified
procedures (6.2%). One patient in four had been
hospitalised at least once in the past 6 months.
Preventive medications comprised statins
(94%), angiotensin-converting enzyme inhibi-
tors or angiotensin II receptor antagonists
(89%), aspirin (85%) and clopidogrel (13%).
Baseline antianginal treatments (Table 2)
comprised beta-blocker monotherapy (45%)
and two-drug combination therapy (41%);
overall, 93% of patients were taking a beta-
blocker alone or in combination. Only 23
patients (3%) were not taking a beta-blocker,
calcium channel blocker or long-acting nitrate,
possibly because of intolerance or
contraindications.
Effect of TMZ 35 mg Add-on Therapy
Over the 6 months angina frequency and
short-acting nitrate use fell significantly (both
p\0.0001) from 5.36 ± 5.38 to 1.12 ± 1.7
attacks/week (Fig. 1a) and from 5.12 ± 5.23 to
0.87 ± 1.43 intakes/week (Fig. 1b). Both fell
significantly from baseline within the first two
treatment weeks.
The proportion of patients with class I ang-
ina increased sixfold (5–30%), while that of
class 3 angina decreased almost fourfold
(27–7%) (Fig. 2). Analysis with respect to
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first-line medication showed that TMZ signifi-
cantly reduced weekly angina frequency inde-
pendently of the physician’s initial treatment
(Fig. 3). Antianginal efficacy in other treatment
groups comprising only a few patients (TMZ
alone, TMZ combined with a calcium channel
blocker or long-acting nitrate, and TMZ com-
bined with two other antianginals) was similar
and consistent with the main results (data not
shown). Walking distance and well-being at
6 months increased significantly (both
p\0.0001) from 336.9 ± 252.9 to 593.6 ±
419.8 m (Fig. 4) and from 44.0 ± 17.3 to
77.3 ± 16.6 (Fig. 5).
Physicians adjusted antianginal treatments
other than TMZ at least once during the study
in 61% of patients. End of study heart rate was
65.8 ± 6.1 bpm and systolic blood pressure
127.4 ± 9 mmHg. The antianginal effect of TMZ
was independent of treatment adjustments,
initial heart rate and systolic blood pressure. It
was also consistent with results in the general
study population (data not shown).
Table 1 Demographics and baseline characteristics of the




Age, years ± SD 861 64.0 ± 9.4
Gender, n (%) 896
Male 415 (46.3)
Female 481 (53.7)
Body mass index kg/
m2 ± SD
873 29.8 ± 4.8







Hypertension 896 830 (93)
Diabetes 896 186 (21)
Heart failure 896 563 (63)
Current smoker 890 137 (15)








896 5.36 ± 5.38
Short-acting nitrate use/
week ± SD
896 5.12 ± 5.23
Systolic blood pressure,
mmHg ± SD
896 147.1 ± 14.3





Class I 45 (5)
Class II 563 (63)





Class IV 4 (\1)
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Tolerability
A total of 881 patients completed the study per
the protocol; 15 patients (1.67%) discontinued
treatment because of patient decision without
explanation (1.2%), death from stroke (0.1%),
hospitalisation for myocardial infarction (0.1%)
and other causes (0.2%). Treatment was well
tolerated and no related serious adverse events
were reported.
DISCUSSION
While clinical trials remain the gold standard
requirement for new drug registration, it is
becoming increasingly apparent that the nec-
essarily standardised, selective and artificial
conditions under which they are conducted
may provide little or no information on how a
drug performs in the clinical practice setting.
Real-world evidence gathered from post-ap-
proval observational studies has a crucial role to
play in perfecting and personalising treatment
delivery. Thus, a large-scale study such as
CHOICE-2, conducted in the field, has provided
powerful evidence of tangible additional bene-
fits from TMZ: significant reductions in attack
frequency and nitrate use, with significant
increases in walking distance and quality of life.
Our study population was typical in that the
treatments being received were in line with
current recommendations: statins 94%,
beta-blockers 93%, aspirin 85% and clopidogrel
13%. Treatment profiles were consistent with
those in recent observational studies of
stable CAD [31]. The proportion of patients
taking a combination of two or more antiangi-
nal drugs at inclusion (48%) was similar to that
reported by the Euro Heart Survey [11].







Two-drug combination 365 (41)
BB ? CCB 219 (24)
BB ? LAN 137 (15)
Other 9 (1)
Three-drug combination
BB ? CCB ? LAN 72 (8)
Not BB, CCB or LAN 23 (3)
Some percentages do not add up to 100% because of
rounding
BB beta-blockers, CCB calcium channel blockers, LAN
long-acting nitrates
Fig. 1 Reduction in mean weekly angina attacks (a) and
short-acting nitrate use (b) before and during trimetazi-
dine administration; LLS
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Most of our patients were in CCS class II and
still experiencing angina despite correct treat-
ment. Adding TMZ 35 mg to their regimen was
thus strictly in line with recommended man-
agement [10]. Efficacy proved significant within
2 weeks. To our knowledge, such early onset of
action has not previously been reported. The
effect increased with time in the overall popu-
lation so that by 6 months it had reduced
weekly angina attacks by 80%. Efficacy was
independent of ongoing background therapy in
that it was consistent and comparable across
treatment groups. The clinical relevance of this
finding is that no additional effect is to be
gained over that of the beta-blocker ? TMZ
combination by adding a calcium channel
blocker or long-acting nitrate or both.
These results confirm those of the ran-
domised clinical trials [14, 32–34] suggesting
that the beta-blocker ? TMZ combination be
considered an optimal first-line approach to
real-world angina. Thus the double-blind
TRIMPOL-II (TRIMetazidine in POLand-II)
study randomised 426 angina patients with
documented CAD to TMZ 60 mg daily or pla-
cebo in addition to first-line metoprolol 100 mg
daily [14]. Exercise testing, nitrate use, and
angina frequency and intensity all showed sig-
nificant improvement at 3 months versus base-
line in the TMZ group compared to placebo.
Fig. 2 Trimetazidine effect on change in CCS angina class
at 6 months; LLS
Fig. 3 Angina attacks/week at baseline and after 2 weeks and 2, 4 and 6 months of trimetazidine administration in the four
ﬁrst-line therapy groups; LLS
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Another randomised double-blind study
compared the addition of TMZ 60 mg daily
versus isosorbide dinitrate 30 mg daily to
first-line propranolol 120 mg daily in 53
patients with angina inadequately controlled by
the beta-blocker alone [35]. Reductions in
attack frequency and nitrate use at 2 months
were both greater in TMZ patients (-63% and
-31%, respectively). Moreover, exercise dura-
tion improved only in TMZ patients (?14% vs.
2% with isosorbide dinitrate), as did time to
1-mm ST-segment depression (?15% vs. ?3%).
Overall, the study found TMZ a more effective
antianginal than the long-acting nitrate.
A recent Ukrainian study added TMZ MR
35 mg bid to the regimen of 1213 outpatients
with angina inadequately controlled by stan-
dard beta-blocker therapy alone or combined
with a long-acting nitrate or calcium channel
blocker [36]. At 2 months TMZ significantly
reduced weekly angina attacks from 6.4 ± 0.1 to
1.9 ± 0.1 and short-acting nitrate use from
5.7 ± 0.1 to 1.2 ± 0.1 (both p\0.001). Not only
was a significant reduction in attack frequency
seen in patients with more severe angina (C7
angina attacks per week) regardless of first-line
therapy, but maximal antianginal efficacy was
achieved only with the dual combination of
beta-blocker ? TMZ.
Angina management has for years centred
on the identification and removal of stenosis.
However, extensive evidence strongly suggests
that coronary artery obstruction is only one
element in a complex multifactorial process
leading to CAD. Obstructive lesions may be
present but not necessarily causative [37]. Since
stable ischaemic syndromes do not obligatorily
require flow-limiting stenosis in a large coro-
nary artery, and since severe stenosis does not
necessarily cause all ischaemic syndromes,
attention should rather focus on the microvas-
culature with attendant myocardial ischaemia
and on the myocardial cell. Placing the
myocardial cell at the centre of the model
allows us to consider, and if possible pre-empt,
all potential pathological inputs that might
drive the progression of ischaemia to unsta-
ble angina, acute myocardial infarction, heart
failure and sudden cardiac death.
TMZ acts directly at cell level by inhibiting
long-chain 3-ketoacyl-CoA thiolase, a mito-
chondrial enzyme involved in fatty acid oxida-
tion. Inhibition of this enzyme decreases fatty
acid oxidation, which then stimulates glucose
oxidation and inhibits glycolysis. These
TMZ-induced chain effects increase the creatine
phosphate/ATP ratio by a significant 33%,
indicating preservation of myocardial high-en-
ergy phosphate levels and ion pump function,
which translates into improved cardiac effi-
ciency and reduced symptoms [38]. These
effects no doubt account for the real-world
benefits our study has shown with add-on TMZ
Fig. 4 Mean walking distance eliciting angina before and
during trimetazidine administration; LLS
Fig. 5 Mean self-rated well-being (visual analogue scale,
0–100) before and during trimetazidine administration;
LLS
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in the up to 40% of stable CAD patients with
persistent angina.
Study Limitations
Despite the limitations inherent in its open-la-
bel, observational, non-interventional design,
which may have introduced bias towards over-
estimation of treatment effect, this study pro-
vides important insights into the real-world
management of stable angina. Strict inclusion
criteria bar access to randomised controlled tri-
als by the broader populations with multiple
comorbidities and risk factors widely present in
real-world practice. This may explain the ele-
vated heart rate and systolic blood pressure at
baseline. Other limitations to mention include
the absence of a placebo group, which leaves
unaddressed the question whether adding a
placebo would have given the same results, and
the absence of daily dose data for the various
antianginals. A further limitation is that
non-interventional trials may underestimate
adverse events; these were not specifically
sought but only evaluated in accordance with
routine pharmacovigilance procedures.
CONCLUSION
The CHOICE-2 study shows add-on TMZ to be a
rapidly effective strategy in the real-world clin-
ical setting for reducing attack frequency and
nitrate use in patients receiving first-line medi-
cation for stable angina. TMZ also increased
walking distance and well-being. These effects
were observed within 2 weeks and persisted for
at least 6 months.
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